Compare WSO & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSO | MDGL |
|---|---|---|
| Founded | 1945 | 2011 |
| Country | United States | United States |
| Employees | 7050 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 12.4B |
| IPO Year | N/A | 2005 |
| Metric | WSO | MDGL |
|---|---|---|
| Price | $387.39 | $551.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $399.00 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 312.3K | 307.9K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $3.02 | $58.39 |
| Revenue Next Year | $5.20 | $48.55 |
| P/E Ratio | $34.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $323.05 | $286.75 |
| 52 Week High | $494.94 | $615.00 |
| Indicator | WSO | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 46.33 | 60.78 |
| Support Level | $355.11 | $498.59 |
| Resistance Level | $388.96 | $572.20 |
| Average True Range (ATR) | 11.32 | 23.12 |
| MACD | -1.38 | 1.78 |
| Stochastic Oscillator | 25.48 | 75.57 |
Watsco is the largest HVAC and refrigeration products distributor in North America with approximately 13% market share. The company primarily operates in the United States (90% of revenue) with significant exposure in the Sunbelt states. Watsco also has operations in Canada, Latin America, and the Caribbean. The company's customer base comprises more than 120,000 dealers and contractors serving the replacement and new-construction HVAC/R markets for residential and light-commercial applications. As much as 20% of residential HVAC units are distributed through Watsco in any given year. Revenue is approximately 75%-80% residential HVAC and 20%-25% commercial, with relatively small exposure to more complex "applied" solutions.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.